Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL3396251 | 0.91 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| SCHEMBL1870609 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| SCHEMBL4675 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| Benzene SCHEMBL28096336 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| Methane SCHEMBL10924043 | 0.87 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| Hydrochloric Acid SCHEMBL9268979 | 0.87 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| Hydrogen Sulfide SCHEMBL28016697 | 0.87 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| Ammonia Solution, Strong SCHEMBL38662792 | 0.87 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| Ethane SCHEMBL10923525 | 0.87 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ETSHRCYP4F2 | |
| Phosphine SCHEMBL27697952 | 0.87 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ETSHRCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506961-B1 | Processes for resolving piperidyl acetamide stereoisomers | CELGENE CORP (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-1612207-B1 | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | CELGENE CORP (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7459560-B2 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060142583-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | KHETANI VIKRAM | 2006-06-29 | — | — | US | disclosed |
| EP-1612207-A1 | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | CELGENE CORPORATION (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6962997-B1 | Process and intermediates for resolving piperidyl acetamide steroisomers | CELGENE CORPORATION (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1082307-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING 2-SUBSTITUTED PIPERIDINE STEREOISOMERS | CELGENE CORP (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1506961-A2 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050014790-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-0983238-B1 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6359139-B1 | REACTING 1-THREO-PIPERIDYL ACETAMIDE WITH AN ALKANOIC ACID IN SOLVNET | CELGENE CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-0983238-A4 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORP (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-0983238-A1 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5965734-A | REACTING 2-SUBSTITUTED PYRIDINE WITH HYDROGEN IN THE PRESENCE OF CATALYST AND ALKANOIC ACID, ADDING AKLYL ALKANOATE, AND THEN REACTING WITH AQUEOUS BASE THEN WITH ACID AND RESOLVING AGENT TO FORM ACID SALTS OF 1-ERYTHRO PIPERIDINE STEREOSIOMERS | CELGENE CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5936091-A | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1998052921-A1 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014790-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | NAAA, DHPS, CTPS2 | CYP19A1 1729/4885ALDH1A1 321/4885LMNA 2492/4885 |
| US-20060142583-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | NAAA, DHPS, CTPS2 | CYP19A1 1729/4885ALDH1A1 321/4885LMNA 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.